AU Patent

AU2022246392B2 — Pharmaceutical composition comprising empagliflozin and uses thereof

Assigned to Boehringer Ingelheim International GmbH · Expires 2024-09-19 · 2y expired

What this patent protects

PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN AND USES THEREOF Abstract The present invention relates to methods for preventing or treating acute or chronic heart failure and for reducing the risk of cardiovascular death, hospitalization for heart failure and other con…

USPTO Abstract

PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN AND USES THEREOF Abstract The present invention relates to methods for preventing or treating acute or chronic heart failure and for reducing the risk of cardiovascular death, hospitalization for heart failure and other conditions in patients with preserved or reduced ejection fraction by administering empagliflozin to the patient.

Drugs covered by this patent

Patent Metadata

Patent number
AU2022246392B2
Jurisdiction
AU
Classification
—
Expires
2024-09-19
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.